Capricor Therapeutics announces four-year data from HOPE-2 OLE study

Capricor Therapeutics (CAPR) announced four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy. The data will be featured in the session titled “Therapies that Slow Progression” at the Parent Project Muscular Dystrophy 2025 Annual Conference, taking place June 21, 2025, in Las Vegas, Nevada. After four years of continuous treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline. Further, a subgroup analysis of patients with baseline LVEF greater than45% showed an even greater clinical benefit, supporting early intervention with Deramiocel to potentially preserve cardiac function. Additionally, treatment continued to slow skeletal muscle disease progression, as measured by Performance of the Upper Limb, with patients experiencing a smaller average decline in the fourth year compared to the first year. Together, these findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time. Deramiocel continues to maintain a favorable safety profile throughout the study.